



Movantik® (naloxegol) – New Warning

- On August 22, 2016, the [FDA approved](#) a new update to the *Warnings and Precautions* section of the [Movantik \(naloxegol\)](#) drug label, regarding severe abdominal pain and/or diarrhea.
 - Movantik is indicated for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
- Reports of severe abdominal pain and/or diarrhea have been reported, some of which resulted in hospitalization. Most of the cases of severe abdominal pain were reported in patients taking the 25 mg dosage. Symptoms generally occurred within a few days of initiation of Movantik.
- Patients should be monitored for the development of abdominal pain and/or diarrhea. Movantik should be discontinued if severe symptoms occur. Movantik may be restarted at 12.5 mg once daily, if appropriate.
- Other warnings and precautions of Movantik include opioid withdrawal and gastrointestinal perforation.
- In addition, the Movantik drug label has been updated with information regarding the administration of crushed tablets mixed in water given orally or via nasogastric tube.
 - Previously, the instructions for Movantik stated to swallow the tablets whole, do not crush or chew.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.